论文部分内容阅读
[目的]研究喉癌中COX-2与P-gp表达的关系,探讨其在喉癌耐药中的作用。[方法]采用免疫组化SP法检测喉癌中的COX-2的表达情况和COX-2阳性组、COX-2阴性组中P-gp的表达情况。[结果]COX-2在喉癌组织中阳性表达率为39.33%,在正常组织中仅5.00%,差异有显著性(P<0.05),COX-2表达与喉癌临床分期及淋巴结转移密切相关。COX-2阳性组中P-gp阳性率为74.29%;COX-2阴性组中为16.67%(P<0.05)。P-gp表达与COX-2表达呈正相关。[结论]COX-2可能参与了P-gp介导的多药耐药的产生,通过干预COX-2的表达可减少肿瘤耐药。
[Objective] To study the relationship between the expression of COX-2 and P-gp in laryngeal carcinoma and its role in the drug resistance of laryngeal carcinoma. [Method] The expression of COX-2 in laryngeal carcinoma and the expression of P-gp in COX-2 negative group and COX-2 negative group were detected by immunohistochemical SP method. [Results] The positive expression rate of COX-2 in laryngeal carcinoma was 39.33% and in normal tissue only 5.00%, the difference was significant (P <0.05). The expression of COX-2 was closely related to the clinical stage and lymph node metastasis . The positive rate of P-gp in COX-2 positive group was 74.29% and in COX-2 negative group was 16.67% (P <0.05). P-gp expression was positively correlated with COX-2 expression. [Conclusion] COX-2 may be involved in the multidrug resistance mediated by P-gp. COX-2 expression can reduce the drug resistance of tumor cells.